Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.
about
TPO receptor agonist for chronic idiopathic thrombocytopenic purpuraMegakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connectionContemporary management of primary immune thrombocytopenia in adultsPathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromesEltrombopag for the treatment of aplastic anemia: current perspectivesThe secret life of a megakaryocyte: emerging roles in bone marrow homeostasis controlEltrombopag in aplastic anemiaBidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.Thrombopoietin and platelet production in chronic immune thrombocytopenia.New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.Toxicities of the thrombopoietic growth factorsPathophysiology and management of chronic immune thrombocytopenia: focusing on what matters.Pathophysiology and therapeutic options in primary immune thrombocytopenia.Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment.Immune thrombocytopenia: no longer 'idiopathic'.Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities.Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.Romiplostim: a review of its use in immune thrombocytopenia.Use of romiplostim for primary immune thrombocytopenia in children.Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications?Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data.Patients with ≥ 20 × 10(9)/l platelets at baseline may have a prompt response to romiplostim during the early phase of treatment: an italian single-institution experience.Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis.Myelofibrosis associated with romiplostim treatment in a patient with immune thrombocytopenia.Positioning new treatments in the management of immune thrombocytopeniaLong-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopeniaPreliminary nonclinical toxicity, pharmacokinetics, and pharmacodynamics of ALXN4100TPO, a thrombopoietin receptor agonist, in CD2F1 mice.Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside.Thrombopoietin receptor agonists in primary immune thrombocytopenia.The biology of thrombopoietin and thrombopoietin receptor agonists.Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation.Romiplostim for management of chemotherapy-induced thrombocytopenia.Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up.Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.Romiplostim as a treatment for immune thrombocytopenia: a review.
P2860
Q24235481-C0EFC889-0973-4612-B926-BF7EB6E42D66Q24607513-D1B874BE-FF0D-49F7-83E0-B5A5F54E0D33Q26853680-463CCB24-24A0-4CD0-B1E4-E9481903E9A0Q26863182-740F05C1-B753-4EA8-AC57-D0A6B41DCF53Q28071710-14E5C49A-7A50-4596-B0E8-FD29B026EFEDQ28082685-C2D10847-C637-4FE8-BB13-F96A098FEA80Q28085299-B00CB26A-68DD-4E27-AD1C-8D98C3B847F8Q31158985-3959837B-BEF7-4DA8-A382-19C9D1F3AB58Q33387153-BCB07FD1-1B19-4206-84BF-9C30D15B92B5Q33387735-CFB6A51A-D0A2-49C0-B6A8-D73317AF3FEAQ33390645-5E6B2BE1-BF17-424D-BA67-7E590C3DB3FBQ33392868-65AF9570-6507-4552-9210-355E068723C6Q33393732-63EF0E84-FF60-4ECD-8E11-79ABC5D4998EQ33395141-9F5FD497-570A-4BE7-9D98-D6F0B6AB3BDEQ33395624-A32A0F04-CEBC-4D62-B90D-8439D9CFC77DQ33395943-89C9C99A-C8E0-4C5D-B8AA-CB61F0D8F016Q33396730-C4521952-858A-4A1F-8BC6-840DEF2451D5Q33397092-C68E7E96-76B9-49E2-A7A1-07BFC0DC565CQ33399598-6A68A662-3073-4379-BEF5-03B419295F73Q33399983-DE6CF646-0AD4-4FFC-9DB5-BFA8AD8839EBQ33401130-4AB80D62-5489-4E0B-A227-D5DD8DA775A7Q33401211-628ADA37-6BAF-4480-96EA-D15D5F429A1FQ33401956-C1347FFF-68A0-4325-983B-5D23E926A381Q33402430-ACD5C4D0-A45F-4D76-B3BD-DDB52E714527Q33402611-082388CA-7D17-434B-A4E3-6A96D38FF3FAQ33403065-FA7F3016-4BD4-447C-AF99-9E60EE082216Q33404095-8FA865AE-F27D-499D-8C18-812F3FB6C813Q33406032-342ABBA3-69E6-41CE-BBE0-F14419E0E9FDQ33406127-4FD87AFC-CC76-420C-A5F6-2198995A3BE6Q33406871-DEF0D2B1-3717-4D36-9013-40BFFE2152CEQ33407110-930090FE-74B4-43DE-871F-3E16CC279043Q33407623-6B044A30-C543-479C-A999-010BCE7C3B76Q33408850-9AB1732A-55C4-42A1-B6B6-1B75E05E0ADDQ33409611-ABE28CB3-E159-44C5-A965-878D05B5C5C4Q33410123-7FE6823A-9FC2-431D-BE79-6F9AD70B480CQ33412605-23C1A79B-CADB-4125-9AB1-025FEDEFA1F1Q33412896-703885E4-B0D6-457A-AEE0-EC1194D5FF50Q33418391-DCF2CF51-8164-4F70-BBCD-00B0DCE44B8DQ33419335-7AB13357-D534-4285-AEA9-AE96972E1060Q33420059-AFF064EC-A84C-4F6A-A868-8C4D39522640
P2860
Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Evaluation of bone marrow reti ...... ents treated with romiplostim.
@ast
Evaluation of bone marrow reti ...... ents treated with romiplostim.
@en
type
label
Evaluation of bone marrow reti ...... ents treated with romiplostim.
@ast
Evaluation of bone marrow reti ...... ents treated with romiplostim.
@en
prefLabel
Evaluation of bone marrow reti ...... ents treated with romiplostim.
@ast
Evaluation of bone marrow reti ...... ents treated with romiplostim.
@en
P2093
P1433
P1476
Evaluation of bone marrow reti ...... ents treated with romiplostim.
@en
P2093
Barbara J Bain
David J Kuter
Ghulam J Mufti
Mark Rutstein
Robert P Hasserjian
Wende Davis
P304
P356
10.1182/BLOOD-2009-05-224766
P407
P577
2009-08-11T00:00:00Z